Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ)
Thiery Vuillemin, Antoine, Poulsen, Mads Hvid, Dourthe, Louis-Marie, Trepiakas, Redas, Lagneau, Edouard, Pintus, Elias Pasquale, Beal-Ardisson, Dominique, Birtle, Alison Jane, Ploussard, Guillaume, Besson, Hervé, Lukac, Martin, Robinson, Paul, Reid, Alison Helen
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article